Visura

Strong early adoption can be misleading — if it's from the wrong customers. Think about it: 1?? Your pilot program is thriving... but with users who can't make purchasing decisions. 2?? Your feedback is stellar... but from a market segment that doesn't align with your long-term strategy. 3?? Your usage metrics are climbing... but without any path to revenue. In reality, early traction from the wrong users can be worse than no traction at all because it leads to misaligned product development and false confidence in market fit. Let the problem go on longer, and you’ll waste resources on unsustainable growth. What early signals have made you rethink your market strategy? Share them with us in the comments.

“We're focusing on enterprise deals.” Are you? Or are you just chasing a long, slow sales cycle that kills momentum? Here's what most healthtech founders don't talk about — enterprise deals are often fool's gold. While everyone celebrates the logos, nobody mentions the: ● 18-month sales cycles that drain resources ● Endless stakeholder meetings that distract from product development ● Complex integration requirements that reshape your roadmap ● Procurement processes that test your team's sanity The reality is that your best path to growth might be targeting mid-market players who can move fast and actually implement your solution. So, start smaller. Move faster. Build momentum. Don't get stuck playing a game of endless tug of war. Want to discuss a sales strategy that actually fits your stage? Let's connect.

Funding isn’t drying up, but the bar is higher than ever. Healthtech and medtech investors are looking beyond big ideas — they want founders who understand unit economics, scalability, and real-world adoption challenges. It’s no longer enough to say “we use AI” or “this will reduce costs.” ?????????????????? ???????? ??????????. How will your technology fit into existing workflows? Can you scale without burning capital too quickly? Will providers or payers actually pay for this? The startups that secure funding in 2025 won’t just have great products. They’ll have answers to the hard questions.

Too many healthtech startups get trapped in an endless cycle of pilots that never turn into real contracts. Hospitals and health systems love pilots because they get to test new solutions with minimal risk — but if you don’t set clear expectations upfront, your product becomes another “nice-to-have” that never makes it past the trial phase. The key? Define success metrics early. Make sure both sides agree on what a successful pilot looks like and what the next step will be if those metrics are met. If there’s no clear path to a contract, reconsider whether the pilot is worth your time. Healthtech sales cycles are long enough — don’t let unnecessary pilots slow you down even more. We're here to help, reach out today.

Early-stage startups don’t require a full-time C-suite team. That’s why many founders start with advisors — to gain insight without heavy overhead. ?????? ???????? ???? ???? ???????? ???? ???????????????????? ???????? ???? ?????????????? ???? ?? ???????????????????? ??????????????????? Here’s how we see this shift working best: ?? Advisory Phase — Strategic guidance, market insights, and an external perspective. Helps shape direction without deep involvement. ?? Fractional Leadership Phase — Hands-on execution, leadership integration, and direct accountability for outcomes. This is where traction accelerates. The best fractional relationships start with trust, starting with an advisory relationship. Advisors who prove value early often become ideal for deeper leadership roles. If your company is growing fast but not ready for a full-time executive, fractional leadership might be the right next step. https://lnkd.in/eJuEf79j

Expanding into the U.S. healthcare market isn’t just about updating your website and hiring a few sales reps. The regulatory landscape, provider networks, and reimbursement models are vastly different from other regions of the world. If you’re an international healthtech or medtech startup looking to break into the U.S. market, here’s where to focus first: ? Understand the regulatory pathway — FDA approval, CPT codes, and reimbursement structures can make or break your market entry. ? Identify the right early adopters — Health systems, private practices, payers, and employers all have different purchasing behaviors. ? Adapt your GTM strategy — The U.S. doesn’t buy like Europe or APAC. Your positioning, sales motion, and clinical validation strategy all need to reflect this. Scaling into the U.S. can be daunting, but the right strategy and partners saves time, capital, and frustration. If you’re navigating this challenge, we can help.

Feeling stretched between driving innovation and managing the day-to-day operations of a growing business? That’s where fractional leadership comes in. By bringing in part-time strategic executives, your startup gains the expertise of seasoned leaders without the full-time overhead. Fractional C-suite support ensures your startup stays focused on what matters — building great products and solutions — while we handle the operations and growth strategies. Don’t navigate this alone. Scale the smart way. Why fractional? https://www.visura.io/faq

True growth stems from experience-driven guidance, strategic insights, and a deep understanding of each startup’s unique journey. Here’s how our primary values drive impactful change for healthtech and medtech leaders: ?? Experience-Driven Excellence: Our founder, Dr. Jon Belsher, brings over 30 years of clinical, executive, and military leadership that sets the foundation for impactful support. ?? Tailored Approach: We recognize that each startup faces its own challenges. Our customized solutions address specific hurdles, ensuring each growth phase aligns with your vision. ?? Operational & Strategic Leadership: From navigating regulations to scaling, we offer the fractional operational guidance and strategic insights needed to prepare your startup for sustainable growth every step of the way. We’re here to guide you from Blueprint to Breakthrough.? Learn more: https://www.visura.io/faq

Most healthtech startups face scaling challenges they’re unprepared for. From securing capital to go-to-market strategy, there are significant roadblocks along the way. That’s where we come in. ?? Let’s discuss your scaling challenges and goals. Reach out for a discovery call with our founder.

Healthtech founders face unique challenges, and the stakes are high. We’ve seen it all — here are some of the most common mistakes founders should avoid: - Skipping proper market research - Trying to do everything alone - Building too inexperienced of a team You can avoid these pitfalls. Don’t let them disrupt you on your path to achieving your goals. More on how we guide founders: https://lnkd.in/g73vpD-4